(Philadelphia, PA) – Temple University Hospital is the first in the Philadelphia region to offer an innovative new treatment for peripheral artery disease (PAD), a life-threatening condition that affects millions of Americans. PAD causes plaque to build up in the arteries that carry blood to the limbs, head and other organs, creating blockages. PAD can lead to a severe blockage in the arteries of the legs or feet and can cause severe lifestyle-limiting leg pains that could potentially require amputation.
Temple is now offering the Lutonix® 035 Drug Coated Balloon PTA Catheter, the first and only treatment of its kind approved for angioplasty for patients with severely blocked femoro-popliteal arteries due to PAD. The new catheter contains an angioplasty balloon, which re-opens the arteries above the knee, and is coated with a low dose of Paclitaxel. When inflated, the balloon applies the drug to the artery wall, inhibiting the growth of new cells at the site of the angioplasty and reducing the risk of restenosis, or recurrence of the blockage.
Riyaz Bashir, MD, Associate Professor of Medicine at Temple University School of Medicine, and Director of Vascular and Endovascular Medicine at Temple University Hospital, performed Temple’s first procedure using the new device on October 14. “This technology is a significant advance in the field of vascular disease treatments,” says Dr. Bashir. “Not only does this reduce the rate of restenosis, which is a common occurrence with these types of blockages, but it is also more likely to preserve these arteries for other treatment options like bypass surgery. We are pleased to be able to offer this option to our patients.”
The Food and Drug Administration approved the new device on October 10.
Editor’s Note: Neither Dr. Bashir nor any member of his immediate family has financial interest in C.R. Bard, Inc., the manufacturer of the Lutonix® 035 Drug Coated Balloon PTA Catheter.
About Temple Health
Temple University Health System (TUHS) is a $1.4 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH), ranked among the “Best Hospitals” in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices. TUHS is affiliated with Temple University School of Medicine.
Temple University School of Medicine (TUSM), established in 1901, is one of the nation’s leading medical schools. Each year, the School of Medicine educates approximately 840 medical students and 140 graduate students. Based on its level of funding from the National Institutes of Health, Temple University School of Medicine is the second-highest ranked medical school in Philadelphia and the third-highest in the Commonwealth of Pennsylvania. According to U.S. News & World Report, TUSM is among the top 10 most applied-to medical schools in the nation.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by Temple University School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.